Book a meeting
DO-BO

What Are the Biggest Challenges & Opportunities of JCA, Dr. Nick Leach?

In this brand new episode of MAP, the Market Access Podcast, our host Dr. Stefan Walzer is joined by Dr. Nick Leach, Market Access expert and managing director at Red Thread, to break down the Joint Clinical Assessment (JCA) process, its impact on pharma, biotech, and medical device companies, and how early advice can shape market access and reimbursement strategies in Europe.

Tune in to learn about JCA’s mandatory requirements, challenges, opportunities, and future developments as companies prepare for the evolving EU market access framework. JCA is changing the market access landscape in Europe – don’t miss out on this insightful discussion!

Related

Can VR and AR Finally Break Through the Barriers in Medical Innovation, Günther Illert?

By

Stefan Walzer

In this episode of the Market Access Podcast, Dr. Stefan Walzer sits down with strategy consultant and XR advocate Günther Illert to explore how virtual, augmented, and extended reality are reshaping healthcare—from patient training and pain therapy to surgical planning and medtech education. Learn how cross-sector collaboration and early adoption—especially outside traditional reimbursement systems—can unlock […]

Why Should Pharma and MedTech Innovators Look at New Zealand, Julius Ohrnberger?

By

Stefan Walzer

Tune in to this new episode of MAP to explore New Zealand’s unique healthcare and reimbursement landscape with Dr. Stefan Walzer and health economist Dr. Julius Ohnberger. Learn how PHARMAC combines HTA and payer roles, why equity and Māori health outcomes are central to market access and what global pharma can gain from launching in […]

Are We Ready for a Cultural Shift Toward AI in Pharma, Elizabeth Shanahan?

By

Stefan Walzer

In this brand new episode of MAP – the Market Access Podcast, Dr. Stefan Walzer sits down with Elizabeth Shanahan, AI Strategy Lead at Sanofi, for a refreshingly honest conversation on the real-world implementation of artificial intelligence in pricing, evidence generation, and HTA processes. From streamlining evidence generation to enhancing pricing strategies and dossier creation, […]